Zacks: Brokerages Expect Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $1.68 Million
Analysts predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will report $1.68 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the highest sales estimate coming in at $2.20 million and the lowest estimate coming in at $1.18 million. Abeona Therapeutics posted sales of $220,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 663.6%. The company is scheduled to issue its next earnings results on Wednesday, November 21st.
According to Zacks, analysts expect that Abeona Therapeutics will report full-year sales of $6.08 million for the current fiscal year, with estimates ranging from $5.63 million to $6.83 million. For the next financial year, analysts expect that the company will post sales of $18.32 million, with estimates ranging from $4.23 million to $43.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%.
Shares of Abeona Therapeutics stock traded down $0.52 on Friday, reaching $9.36. The company’s stock had a trading volume of 591,945 shares, compared to its average volume of 657,835. The stock has a market capitalization of $419.98 million, a PE ratio of -14.18 and a beta of 1.77. Abeona Therapeutics has a 52-week low of $8.52 and a 52-week high of $22.00.
Large investors have recently modified their holdings of the company. Fortaleza Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter worth approximately $104,000. Parkside Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $160,000. United Services Automobile Association acquired a new stake in shares of Abeona Therapeutics in the second quarter worth approximately $162,000. Trexquant Investment LP acquired a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $163,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $235,000. 76.38% of the stock is currently owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.